146 related articles for article (PubMed ID: 8041895)
21. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients.
Suwinski R; Sowa A; Rutkowski T; Wydmanski J; Tarnawski R; Maciejewski B
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):399-412. PubMed ID: 12738315
[TBL] [Abstract][Full Text] [Related]
22. [Timing and duration of postoperative radiotherapy in patients with laryngeal cancer].
Milecki P; Kruk-Zagajewska A; Stryczyńska G
Otolaryngol Pol; 2002; 56(3):307-11. PubMed ID: 12162018
[TBL] [Abstract][Full Text] [Related]
23. [Long-term results and cause of failure analysis in larynx cancer patients irradiated conventionally and with accelerated fractionation schedules in 1995-1998].
Szutkowski Z; Kawecki A; Jarząbski A
Otolaryngol Pol; 2014; 68(6):320-7. PubMed ID: 25441938
[TBL] [Abstract][Full Text] [Related]
24. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3.
Terhaard CH; Kal HB; Hordijk GJ
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):62-9. PubMed ID: 15850903
[TBL] [Abstract][Full Text] [Related]
25. The different clinical presentation, behaviour and prognosis of carcinomas originating in the epilarynx and the lower supraglottis.
Van den Bogaert W; Ostyn F; van der Schueren E
Radiother Oncol; 1983 Nov; 1(2):117-31. PubMed ID: 6680217
[TBL] [Abstract][Full Text] [Related]
26. Radiation treatment of T1-T4 squamous cell carcinoma of the larynx: a retrospective analysis and long-term follow-up of 135 patients.
Bergqvist M; Brodin O; Pouzon A; Linder A; Hesselius P; Blomquist E
Anticancer Res; 2002; 22(2B):1239-42. PubMed ID: 12168932
[TBL] [Abstract][Full Text] [Related]
27. Early-stage glottic cancer: importance of dose fractionation in radiation therapy.
Kim RY; Marks ME; Salter MM
Radiology; 1992 Jan; 182(1):273-5. PubMed ID: 1727295
[TBL] [Abstract][Full Text] [Related]
28. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer?
Van den Bogaert W; Van der Leest A; Rijnders A; Delaere P; Thames H; van der Schueren E
Radiother Oncol; 1995 Sep; 36(3):177-82. PubMed ID: 8532903
[TBL] [Abstract][Full Text] [Related]
29. Do overall treatment time, field size, and treatment energy influence local control of T1-T2 squamous cell carcinomas of the glottic larynx?
Fein DA; Lee WR; Hanlon AL; Ridge JA; Curran WJ; Coia LR
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):823-31. PubMed ID: 8598359
[TBL] [Abstract][Full Text] [Related]
30. Local control in T3 laryngeal cancer treated with radical radiotherapy, time dose relationship: the concept of nominal standard dose and linear quadratic model.
Terhaard CH; Karim AB; Hoogenraad WJ; Tjho-Heslinga R; Keus RB; Mehta DM; Reichgelt BA; Hordijk GJ
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1207-14. PubMed ID: 2045295
[TBL] [Abstract][Full Text] [Related]
31. Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx.
Wendt CD; Peters LJ; Ang KK; Morrison WH; Maor MH; Goepfert H; Oswald MJ
Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):1057-62. PubMed ID: 2808039
[TBL] [Abstract][Full Text] [Related]
32. Compensation for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial.
Roberts SA; Hendry JH; Swindell R; Wilkinson JM; Hunter RD
Radiother Oncol; 2004 Jan; 70(1):63-74. PubMed ID: 15036854
[TBL] [Abstract][Full Text] [Related]
33. Clinical radiobiology of glottic T1 squamous cell carcinoma.
Skladowski K; Tarnawski R; Maciejewski B; Wygoda A; Slosarek K
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):101-6. PubMed ID: 9989520
[TBL] [Abstract][Full Text] [Related]
34. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.
Touboul E; Schlienger M; Buffat L; Lefkopoulos D; Pène F; Parc R; Tiret E; Gallot D; Malafosse M; Laugier A
Cancer; 1994 Mar; 73(6):1569-79. PubMed ID: 8156483
[TBL] [Abstract][Full Text] [Related]
35. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control.
Fein DA; Mendenhall WM; Parsons JT; Million RR
Int J Radiat Oncol Biol Phys; 1993 Mar; 25(4):605-11. PubMed ID: 8454477
[TBL] [Abstract][Full Text] [Related]
36. The steepness of the dose response curve both for tumor cure and normal tissue injury.
Stewart JG; Jackson AW
Laryngoscope; 1975 Jul; 85(7):1107-11. PubMed ID: 807783
[TBL] [Abstract][Full Text] [Related]
37. The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma.
Eriksen JG; Steiniche T; Overgaard J;
Acta Oncol; 2005; 44(1):50-8. PubMed ID: 15848906
[TBL] [Abstract][Full Text] [Related]
38. Squamous cell carcinoma of the supraglottic larynx treated with radical irradiation: analysis of treatment parameters and results.
Mendenhall WM; Million RR; Cassisi NJ
Int J Radiat Oncol Biol Phys; 1984 Dec; 10(12):2223-30. PubMed ID: 6439701
[TBL] [Abstract][Full Text] [Related]
39. The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx.
Maciejewski B; Preuss-Bayer G; Trott KR
Int J Radiat Oncol Biol Phys; 1983 Mar; 9(3):321-8. PubMed ID: 6841183
[TBL] [Abstract][Full Text] [Related]
40. Role of accelerated fractionated irradiation for supraglottic carcinoma: assessment of results.
Wang CC; Nakfoor BM; Spiro IJ; Martins P
Cancer J Sci Am; 1997; 3(2):88-91. PubMed ID: 9099458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
